SCHEMBL535853

SCHEMBL535853

CCOC(=O)c1c(-c2ccccc2)noc1C(O[SiH](C)C)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
LMNA P02545 4/20 0.47
HPGD P15428 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 3/20 0.47
PTBP1 P26599 2/20 0.47
POLB P06746 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
ADORA3 P0DMS8 4/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GABRA5 P31644 1/20 0.44
GAA P10253 2/20 0.43
CYP3A4 P08684 1/20 0.43
ATM Q13315 1/20 0.43
CACNA1F O60840 1/20 0.43
CACNA1D Q01668 1/20 0.43
CACNA1S Q13698 1/20 0.43
CACNA1C Q13936 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL536351 0.78 NR1H4 (0.41) GABRA5
SCHEMBL536297 0.75 TSHR (0.74) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL31526266 0.74 PTGS1 (0.72) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL14711335 0.74 POLB (0.57) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL2776267 0.73 TSHR (0.70) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL14711337 0.73 POLB (0.56) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL3940991 0.73 POLB (0.56) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL4088587 0.73 ALDH1A1 (0.59) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL535854 0.73 TSHR (0.48) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E
SCHEMBL1225880 0.72 POLB (0.56) ALDH1A1LMNAHPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414354-B1 Hydroxy-methyl isoxazole derivatives as gaba a modulators HOFFMANN LA ROCHE (CH) 2012-12-12 EP disclosed
US-8222246-B2 Substituted isoxazoles HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
EP-2414354-A1 Hydroxy-methyl isoxazole derivatives as gaba a modulators F. Hoffmann-La Roche AG (CH) 2012-02-08 EP disclosed
WO-2010112475-A1 HYDROXY-METHYL ISOXAZOLE DERIVATIVES AS GABA A MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-07 WO disclosed
US-20100256127-A1 SUBSTITUTED ISOXAZOLES ROCHE PALO ALTO LLC 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256127-A1 SUBSTITUTED ISOXAZOLES GABRA5, GABRA1, GABRA3 ALDH1A1 426/4885LMNA 4042/4885HPGD 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.